Targeted and synergistic therapy for hepatocellular carcinoma: monosaccharide modified lipid nanoparticles for the co-delivery of doxorubicin and sorafenib

Duan, Wendu; Liu, Yan

doi:10.2147/dddt.s166402

Cited by 46 publications

(20 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 27–31 ] Besides, various nanocarriers with special properties have been utilized for codelivery of chemotherapeutics, such as doxorubicin, cisplatin, and gemcitabine with sorafenib to enhance antitumor efficiency and overcome the limitations associated with conventional drugs. [ 32–36 ]…”

Section: Current Molecular Therapiesmentioning

confidence: 99%

Improvement in the Current Therapies for Hepatocellular Carcinoma Using a Systems Medicine Approach

et al. 2020

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer‐related death primarily due to the lack of effective targeted therapies. Despite the distinct morphological and phenotypic patterns of HCC, treatment strategies are restricted to relatively homogeneous therapies, including multitargeted tyrosine kinase inhibitors and immune checkpoint inhibitors. Therefore, more effective therapy options are needed to target dysregulated metabolic and molecular pathways in HCC. Integrative genomic profiling of HCC patients provides insight into the most frequently mutated genes and molecular targets, including telomerase reverse transcriptase, the TP53 gene, and the Wnt/β‐catenin signaling pathway oncogene (CTNNB1). Moreover, emerging techniques, such as genome‐scale metabolic models may elucidate the underlying cancer‐specific metabolism, which allows for the discovery of potential drug targets and identification of biomarkers. De novo lipogenesis has been revealed as consistently upregulated since it is required for cell proliferation in all HCC patients. The metabolic network‐driven stratification of HCC patients in terms of redox responses, utilization of metabolites, and subtype‐specific pathways may have clinical implications to drive the development of personalized medicine. In this review, the current and emerging therapeutic targets in light of molecular approaches and metabolic network‐based strategies are summarized, prompting effective treatment of HCC patients.

show abstract

Section: Current Molecular Therapiesmentioning

confidence: 99%

Improvement in the Current Therapies for Hepatocellular Carcinoma Using a Systems Medicine Approach

et al. 2020

View full text Add to dashboard Cite

show abstract

“…CIS/5-FU LPHNs inhibited tumor growth greater than free CIS/5-FU with lower drug contents. Ligands modified LPHNs were proved to exhibit the most potent anti-tumor activity among all the groups related to the targeted ability of the ligands (Duan & Liu, 2018 ). The same phenomenon was found in this section that TAB-CIS/5-FU LPHNs inhibiter the in vivo tumor growth better than that of CIS/5-FU LPHNs and other formulas.…”

Section: Discussionmentioning

confidence: 99%

Chemo-immune synergetic therapy of esophageal carcinoma: trastuzumab modified, cisplatin and fluorouracil co-delivered lipid–polymer hybrid nanoparticles

Wang²,

Hong

2020

Drug Delivery

View full text Add to dashboard Cite

Esophageal cancer is the sixth most common cause of cancer-related death worldwide. Peptide modified nanoparticles have been engineered as novel strategies to improve esophageal adenocarcinoma (EAC) therapy. This study aimed to develop a trastuzumab (TAB) modified system for the delivery of cisplatin (CIS) and fluoropyrimidine (5-FU). In the present study, CIS and 5-FU co-encapsulated lipid–polymer hybrid nanoparticles (CIS/5-FU LPHNs) were prepared. TAB was conjugated to the surface of CIS/5-FU LPHNs to achieve TAB decorated CIS/5-FU LPHNs (TAB-CIS/5-FU LPHNs). After the in vitro assessment, a subcutaneous model was used for the in vivo study. The mean diameter of LPNHs was around 100 nm, with higher encapsulation efficacy (EE) of about 90%. The LPNHs was stable and able to release drugs in sustained manners. 63.9% of cell uptake was achieved by TAB-CIS/5-FU LPHNs, with the best in vivo antitumor ability. The best synergistic effect with the lowest CI value (0.68) was achieved at the ratio of 1/1, which was determined for the dosage of drugs in the LPHNs preparation. TAB-CIS/5-FU LPHNs provide a new strategy for synergistic treating of EAC with higher efficacy and reduced side effects, introducing this system as a candidate for EAC therapy.

show abstract

“…significantly inhibited autophagy and enhanced the antitumor effect of SF on HepG2 xenograft tumor mouse model. The synergistic effect of chemotherapeutic agent DOX and molecular targeted drug SF was evaluated by Duan and coworkers 156. In this study, the SF-loaded NAcGal-DOX lipid nanoparticle (NAcGal-DOX/SF LNP) was intravenously injected into HepG2 hepatoma-bearing BALB/c mice, and it showed a higher antitumor efficiency than the single drug-loaded LNPs toward HepG2 hepatoma in vitro and in vivo .…”

Section: Chemotherapy and Molecular Targeted Therapy Of Hepatoma Withmentioning

confidence: 99%

Evaluation of Polymer Nanoformulations in Hepatoma Therapy by Established Rodent Models

Wang

Zhang

et al. 2019

Theranostics

View full text Add to dashboard Cite

Hepatoma is one of the most severe malignancies usually with poor prognosis, and many patients are insensitive to the existing therapeutic agents, including the drugs for chemotherapy and molecular targeted therapy. Currently, researchers are committed to developing the advanced formulations with controlled drug delivery to improve the efficacy of hepatoma therapy. Numerous inoculated, induced, and genetically engineered hepatoma rodent models are now available for formulation screening. However, animal models of hepatoma cannot accurately represent human hepatoma in terms of histological characteristics, metastatic pathways, and post-treatment responses. Therefore, advanced animal hepatoma models with comparable pathogenesis and pathological features are in urgent need in the further studies. Moreover, the development of nanomedicines has renewed hope for chemotherapy and molecular targeted therapy of advanced hepatoma. As one kind of advanced formulations, the polymer-based nanoformulated drugs have many advantages over the traditional ones, such as improved tumor selectivity and treatment efficacy, and reduced systemic side effects. In this article, the construction of rodent hepatoma model and much information about the current development of polymer nanomedicines were reviewed in order to provide a basis for the development of advanced formulations with clinical therapeutic potential for hepatoma.

show abstract

Targeted and synergistic therapy for hepatocellular carcinoma: monosaccharide modified lipid nanoparticles for the co-delivery of doxorubicin and sorafenib

Cited by 46 publications

References 40 publications

Improvement in the Current Therapies for Hepatocellular Carcinoma Using a Systems Medicine Approach

Improvement in the Current Therapies for Hepatocellular Carcinoma Using a Systems Medicine Approach

Chemo-immune synergetic therapy of esophageal carcinoma: trastuzumab modified, cisplatin and fluorouracil co-delivered lipid–polymer hybrid nanoparticles

Evaluation of Polymer Nanoformulations in Hepatoma Therapy by Established Rodent Models

Contact Info

Product

Resources

About